Personalised risk-directed clot prevention for patients with cancer [ 1/1/2021 - 12/31/2025 ]

Research Grant

Brief description Blood clots are a leading cause of death among cancer patients, second only to cancer itself. This EL1 program includes clinical and laboratory studies to assess the impact of personalised clot prevention for patients receiving cancer treatments in ambulatory care settings. Laboratory studies and evaluation of outcomes among ‘real-world’ patients with cancers at high risk of developing blood clots, will improve understanding of both clots and cancer, to advance research and clinical practice.

Funding Amount $645,205

Funding Scheme Investigator Grants

Chief Investigator Dr Marliese Alexander

Notes Emerging Leadership 1